James Maher, MD
Medical Oncology · Cincinnati, OHNPI 1962440305
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $437 and has fallen 59.3% since, to $178 in 2025. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 53 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$218
- AstraZeneca$141
- Pfizer$116
- Tempus AI, Inc$115
- Siemens Medical Solutions USA, Inc.$105
- Eisai Inc.$80
- plus $530 from 18 others
Across 17 payments — averaging $12,080 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$192K
- Eli Lilly$13K
What the payments were for
- Food & beverage$1,25696%
- Education$494%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 3 | $218 |
| AstraZeneca(2 entities) | 7 | $141 |
| Pfizer | 7 | $116 |
| Tempus AI, Inc | 2 | $115 |
| Siemens Medical Solutions USA, Inc. | 1 | $105 |
| Eisai Inc. | 4 | $80 |
| Array Biopharma Inc | 4 | $63 |
| GSK | 3 | $56 |
| Immunocore Limited | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $42 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $32 |
| Immunogen, Inc. | 1 | $30 |
| Novartis | 2 | $29 |
| Sanofi | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$202
- SPECT Symbia Evo$105
How this compares
$1,306 in reported general payments places this provider in the 35th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 44 | $619,341 |
| ErleadaApalutamide | 33 | $428,658 |
| ImbruvicaIbrutinib | 12 | $195,838 |
| NubeqaDarolutamide | 14 | $188,268 |
| OrgovyxRelugolix | 17 | $45,074 |
| XareltoRivaroxaban | 32 | $32,095 |
| Imatinib Mesylate | 34 | $21,992 |
| EliquisApixaban | 26 | $14,796 |
| RybelsusSemaglutide | 13 | $12,388 |
| Abiraterone Acetate | 14 | $2,790 |
| Potassium Chloride | 53 | $1,478 |
| Pregabalin | 31 | $948 |
| Hydrocortisone | 20 | $855 |
| Gabapentin | 65 | $797 |
| Anastrozole | 45 | $647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $12 | $619,34144 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $32 | $195,83812 claims |
| PfizerEliquis | $116 | $14,79626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Cincinnati
- Elyse LowerCincinnati$312K
- John MorrisCincinnati$16K
- Leslie OleksowiczCincinnati$14K
- Gina ChungCincinnati$13K
- David CarboneColumbus$438K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.